Tencent, Guoxin co-lead $97m Series E round in Chinese biopharma Evopoint

Tencent, Guoxin co-lead $97m Series E round in Chinese biopharma Evopoint

Eudora Wang

21 February, 2024

Edited by: Joymitra Rai

biopharmaceuticalCICC CapitalEvopoint BiosciencesGICGuoxin InvestmentLoyal Valley CapitalSTAR MarketTencent

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter

You may also like

Read more from Greater China

Nikkei Logo
DealStreetAsia Logo
About Us
Team
Advertise
Contact
Careers
Blog
Privacy Policy
Terms & Conditions
© Copyright DEALSTREETASIA 2014-2025 All rights reserved.